Koen A. Marijt

Immunology and Microbiology · Life Sciences

13h-index1.5kcitations27works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(17), Cancer Immunotherapy and Biomarkers(13), Immune Cell Function and Interaction(9), CAR-T cell therapy research(4), T-cell and B-cell Immunology(3)

Publications27 total

Data from Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors
2023Open Access
Data from Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors
2023Open Access
Supplementary Data from Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors
2023Open Access
Supplementary Data from Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors
2023Open Access
Association of cognitive function with increased risk of cancer death and all-cause mortality: Longitudinal analysis, systematic review, and meta-analysis of prospective observational studies
PLoS ONE·2022· 12 citedOpen Access
Holland Varia
KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences)·2022
Holland Varia
KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences)·2022
Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement
Cancer Immunology Immunotherapy·2021· 9 citedOpen Access
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
Journal for ImmunoTherapy of Cancer·2020· 60 citedOpen Access
Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors
Cancer Immunology Research·2020· 15 citedOpen Access
Abstract B26: Prorapeutic vaccination against shared antigens induced in future tumors
Cancer Immunology Research·2020
Therapeutic targeting of immune escaped cancers
Leiden Repository (Leiden University)·2020Open Access
To TAP or not to TAP: alternative peptides for immunotherapy of cancer
Current Opinion in Immunology·2020· 21 citedOpen Access
Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity
Nature Communications·2019· 62 citedOpen Access
Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling
Journal for ImmunoTherapy of Cancer·2019· 81 citedOpen Access
TEIPP peptides: exploration of unTAPped cancer antigens
OncoImmunology·2019· 8 citedOpen Access
Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy
Nature Medicine·2019· 236 citedOpen Access
Abstract B111: Vaccination against TAP downregulation-induced neoantigens to prevent future tumor development in the setting of recurrence or premalignancy
Cancer Immunology Research·2019
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines
Cell·2018· 317 citedOpen Access
Identification of non-mutated neoantigens presented by TAP-deficient tumors
The Journal of Experimental Medicine·2018· 69 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Thorbald van Hall(18), Brett Schrand(8), Ailem Rabasa(8), Agata Levay(8), Vikas Dudeja(8), Eli Gilboa(8), Sjoerd H. van der Burg(7), Greta Garrido(7), Francesca D’Eramo(7), Anthony Ferrantella(7), Deukwoo Kwon(6), Diane M. Da Silva(5), Zhuoran Zhang(5), Marcin Kortylewski(5), W. Martin Kast(5), Marjolein Sluijter(3), Laura Blijleven(3), Elien M. Doorduijn(3), Nadine van Montfoort(2), Teresa Peterson(2)